Denmark's Chemometec Q1 revenue rises 28% on instrument sales

ChemoMetec A/S

05/11/2026 16:52

Overview
Denmark cell counting instrument maker's Q1 revenue rose 28% yr/yr, led by instrument sales growth
Q1 EBITDA rose 46%, supported by higher revenue, cost control and improved gross margin
Company maintained full-year revenue and EBITDA guidance after strong Q1

Outlook
Company maintains 2026/27 revenue guidance at DKK 570-605 mln
Company maintains 2026/27 EBITDA guidance at DKK 335-360 mln
Company sees geopolitical and macroeconomic uncertainty as potential risks to customer investment decisions

Result Drivers
INSTRUMENT SALES - Q1 revenue growth was mainly driven by higher sales of instruments, especially the NC-203
CORE BUSINESS AREA - LCB (Life science research, Cell and gene therapy and Bioprocessing) was up by 31% in Q1, with the segment's market revenue accounting for 96% of total revenue 
COST CONTROL AND MARGINS - Co attributed EBITDA growth to strict cost control and improved gross margin on new XcytoMatic products

Company press release: ID:nGNEbyn153

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EBITDA
 
DKK 100.3 mln
 
Q1 EBITDA Margin
 
63%
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Chemometec A/S is DKK660.00, about 2.3% above its November 4 closing price of DKK645.00
The stock recently traded at 44 times the next 12-month earnings vs. a P/E of 33 three months ago

Reuters Recommended Reads
Nov 3 - Denmark's ChemoMetec lifts FY outlook on strong instrument demand, lower costs
Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises
Nov 3 - Devyser Q3 sales rise on portfolio expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)